• About Us
  • Overview
  • Strategy
  • Management >
    • Board of Directors
    • Senior Management
  • Scientific Advisory Board
  • Job Opportunities
• Clinical Trials
  • Overview
• Products
  • Advanced Pipeline >
    • TroVax^®
    • ProSavin^®
    • Hi-8 MEL^®
    • MetXia^®
    • RetinoStat^®
  • Early-stage Pipeline >
    • StarGen^®
    • MoNuDin^®
    • SMN-1G
    • Innurex^®
    • ReQuinate^®
    • ImmStat^®
    • EndoAngio-GT
    • Targeted Antibody
• Technology
  • Gene Delivery Technologies
  • Gene Discovery and Target Validation
  • Antibody Delivery
  • Hypoxia Response Element
• Collaborations
  • Corporate Partnerships
  • Technology Licence Agreements
  • Scientific Collaborations and Advisors
• Investors
  • Financing History
  • Accounts
  • Share Price
  • Presentation >
    • Interim Results August 2008
    • Annual General Meeting May 2008
    • Annual Results March 2007
  • Web Casts
  • Announcements
  • Shareholder Meetings
  • Contact
• News
  • Announcements
  • Events
  • Media Coverage
• Contact Us
  • UK >
    • Contacts
    • Directions
    • Map
  • USA >
    • Contacts
    • Directions
    • Map

Oxford BioMedica has developed proprietary gene delivery and transfer technologies that are used to create vaccines, gene therapies and cell-based therapies for the treatment of a broad range of diseases.

Oxford BioMedica's proprietary LentiVector^® technology represents the most advanced tool currently available for the treatment of chronic diseases such as neuro-degenerative, ocular and cardiovascular disease. The Company's retroviral vectors and novel production systems have enabled the development of gene-based products for enhancing existing cancer therapies. In addition the Company has proprietary products that exploit pox viruses as cancer vaccines and adenoviruses for cell engineering.

LENTIVECTOR
LentiVector is a new gene delivery vector based on lentiviruses. LentiVector systems contain only the few viral components required for efficient gene delivery. These so-called ‘minimal vectors’ are now candidates for clinical use as gene delivery vehicles. Oxford BioMedica has shown that minimal lentiviral vectors are able to deliver genes to a wide range of dividing and non-dividing cells, including neurons in the brain. Oxford BioMedica has pending and granted patents on the technology, providing a sound basis for freedom-to-operate in this field.

LENTIVECTOR TECHNOLOGY
A proprietary gene transfer system based on the lentivirus Equine Infectious Anaemia Virus (EIAV).

LENTIVECTOR APPLICATIONS
Gene therapy
Transgenesis
Stem cell manipulation
Somatic disease models
Target validation
Gene discovery

INTELLECTUAL PROPERTY
Oxford BioMedica has broad patent protection worldwide.

COMMERCIALISATION STRATEGY
Oxford BioMedica is seeking partners who wish to use LentiVector for any of its applications.

PARTNERS / LICENSEES
Biogen Idec, GlaxoSmithKline, Merck & Co., Pfizer and Sigma-Aldrich.

Website by College Hill - Life Sciences